Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases.

Autor: Leduc S; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., De Schepper M; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.; Department of Pathology, University Hospitals Leuven, Leuven, Belgium., Richard F; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Maetens M; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Pabba A; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Borremans K; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.; Department of Gynecological Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium., Jaekers J; Department of Abdominal Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium., Latacz E; Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium., Zels G; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.; Department of Pathology, University Hospitals Leuven, Leuven, Belgium., Bohlok A; Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Van Baelen K; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.; Department of Gynecological Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium., Nguyen HL; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Geukens T; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Dirix L; Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium., Larsimont D; Department of Anatomopathology, Institut Jules Bordet, Brussels, Belgium., Vankerckhove S; Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Santos E; General Surgery Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal., Oliveira RC; General Surgery Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal., Dede K; Department of Surgical Oncology, Uzsoki Hospital, Budapest, Hungary., Kulka J; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary., Borbala S; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary., Salamon F; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary., Madaras L; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.; Department of Pathology, Uzsoki Hospital, Budapest, Hungary., Marcell Szasz A; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary., Lucidi V; Department of Abdominal Surgery, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium., Meyer Y; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Topal B; Department of Abdominal Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium., Verhoef C; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Engstrand J; Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden., Moro CF; Department of Biosciences and Nutrition, Karolinska Institute, Huddinge and Karolinska University Hospital, Solna, Sweden., Gerling M; Department of Biosciences and Nutrition, Karolinska Institute, Huddinge and Karolinska University Hospital, Solna, Sweden., Bachir I; Department of Anesthesiology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Biganzoli E; Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) 'L. Sacco' & DSRC, LITA Vialba campus, University of Milan, Milan, Italy., Donckier V; Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Floris G; Department of Pathology, University Hospitals Leuven, Leuven, Belgium.; Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, KU Leuven, Leuven, Belgium., Vermeulen P; Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium., Desmedt C; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium. christine.desmedt@kuleuven.be.
Jazyk: angličtina
Zdroj: NPJ breast cancer [NPJ Breast Cancer] 2023 Dec 15; Vol. 9 (1), pp. 100. Date of Electronic Publication: 2023 Dec 15.
DOI: 10.1038/s41523-023-00602-6
Abstrakt: Liver is the third most common organ for breast cancer (BC) metastasis. Two main histopathological growth patterns (HGP) exist in liver metastases (LM): desmoplastic and replacement. Although a reduced immunotherapy efficacy is reported in patients with LM, tumor-infiltrating lymphocytes (TIL) have not yet been investigated in BCLM. Here, we evaluate the distribution of the HGP and TIL in BCLM, and their association with clinicopathological variables and survival. We collect samples from surgically resected BCLM (n = 133 patients, 568 H&E sections) and post-mortem derived BCLM (n = 23 patients, 97 H&E sections). HGP is assessed as the proportion of tumor liver interface and categorized as pure-replacement ('pure r-HGP') or any-desmoplastic ('any d-HGP'). We score the TIL according to LM-specific guidelines. Associations with progression-free (PFS) and overall survival (OS) are assessed using Cox regressions. We observe a higher prevalence of 'any d-HGP' (56%) in the surgical samples and a higher prevalence of 'pure r-HGP' (83%) in the post-mortem samples. In the surgical cohort, no evidence of the association between HGP and clinicopathological characteristics is observed except with the laterality of the primary tumor (p value = 0.049) and the systemic preoperative treatment before liver surgery (p value = .039). TIL is less prevalent in 'pure r-HGP' as compared to 'any d-HGP' (p value = 0.001). 'Pure r-HGP' predicts worse PFS (HR: 2.65; CI: (1.45-4.82); p value = 0.001) and OS (HR: 3.10; CI: (1.29-7.46); p value = 0.011) in the multivariable analyses. To conclude, we demonstrate that BCLM with a 'pure r-HGP' is associated with less TIL and with the worse outcome when compared with BCLM with 'any d-HGP'. These findings suggest that HGP could be considered to refine treatment approaches.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: